Stay updated on Nivolumab Plus ABI-009 in Sarcoma: Clinical Trial
Sign up to get notified when there's something new on the Nivolumab Plus ABI-009 in Sarcoma: Clinical Trial page.

Latest updates to the Nivolumab Plus ABI-009 in Sarcoma: Clinical Trial page
- ChecktodayChange DetectedDifference1%
- Check8 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.SummaryDifference1%
- Check15 days agoChange DetectedDifference0.9%
- Check22 days agoChange DetectedThe webpage has been updated to reflect a new version of the study, with the addition of a new collaborator, Aadi Bioscience, Inc., and a new revision number, v2.15.0. Additionally, some detailed descriptions of the study objectives and eligibility criteria have been removed.SummaryDifference45%
- Check29 days agoChange DetectedThe web page has updated its version from v2.14.3 to v2.14.4, and a date has been added for February 17, 2025. However, the deletion of the date March 25, 2025, does not significantly impact the core content.SummaryDifference1%
- Check37 days agoChange DetectedThe page has been updated to include information on Ewing Sarcoma while removing references to Lymphosarcoma, indicating a shift in focus towards Ewing Sarcoma. Additionally, the revision number has been updated from v2.14.2 to v2.14.3.SummaryDifference1%
Stay in the know with updates to Nivolumab Plus ABI-009 in Sarcoma: Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab Plus ABI-009 in Sarcoma: Clinical Trial page.